STTK — Shattuck Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1680367 ·
Last close
$5.66
Market Cap
$568.06M
52W High
$8.33
52W Low
$1.70
ADV30
1,359,060
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -16,155,000 | -15,152,000 | 220,667,000 | 63,299,000 | 9,531,000 |
| Mar 2026 | 0 | — | -15,545,000 | -14,767,000 | 102,121,000 | 90,419,000 | 6,286,000 |
| Dec 2025 | 0 | — | -13,371,000 | -12,593,000 | 91,026,000 | 54,192,000 | 8,636,000 |
| Sep 2025 | 1,000,000 | — | -10,716,000 | -10,056,000 | 100,333,000 | 42,548,000 | 7,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,274,000
Investing CF
$361,000
Financing CF
$70,434,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-445,296,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-52,664,000
Pretax Income TTM
$-49,874,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000,000
EBITDA
$-52,140,000
Free Cash Flow
$-21,216,624
Enterprise Value
$416,623,168
Total Cash
$208,303,008
Total Debt
$2,674,000
Shares Out
100,363,253
Trailing EPS
$-0.44
Book Value
$2.10
ROE
-39.2%
ROA
-24.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,000,000 | -51,508,000 | -48,809,000 | 91,026,000 | 8,636,000 | 82,390,000 | -39,882,000 |
| Dec 2024 | 5,721,000 | -80,567,000 | -75,410,000 | 91,049,000 | 11,423,000 | 79,626,000 | -60,515,000 |
| Dec 2023 | 1,657,000 | -91,957,000 | -87,298,000 | 159,564,000 | 14,859,000 | 144,705,000 | -81,228,000 |
| Dec 2022 | 652,000 | -103,329,000 | -101,945,000 | 205,324,000 | 29,167,000 | 176,157,000 | -94,498,000 |
TTM Snapshot
Revenues TTM
$1,000,000
NetIncome TTM
$-49,874,000
OpCashFlow TTM
—
Assets (Latest)
$102,121,000
Forward EPS
$-0.52
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $5.66 · call oi: 611 · put oi: 3,515Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMP | IMMUTEP Ltd | $565.91M | $3.84 | — |
| CRMD | CorMedix Inc. | $570.55M | $7.32 | — |
| MNPR | Monopar Therapeutics | $563.69M | $83.98 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $576.82M | $7.13 | — |
| EVO | Evotec SE | $557.96M | $1.57 | — |
News headlines (Yahoo Finance, 1h cache)
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
2026-10-01 11:00 · Yahoo
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
2026-09-02 20:05 · Yahoo
What Shattuck Labs Stock Topped the Market on Monday
2026-08-24 22:23 · Yahoo
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
2026-08-13 13:55 · Yahoo
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-11 10:15 · Yahoo
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
2026-07-24 22:27 · Yahoo
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
2026-06-09 12:00 · Yahoo
Shattuck Labs Announces Phase 1 Results for SL-325
2026-06-08 10:00 · Yahoo
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
2026-06-05 20:05 · Yahoo
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
2026-05-11 11:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.